April 3, 2026
Experts discuss mainstreaming genetic testing in breast cancer to guide personalized surgical decisions and targeted therapies for better outcomes.
April 2, 2026
Experts discuss holistic breast cancer survivorship, linking endocrine therapy to metabolic health, lifestyle interventions, and the role of GLP-1 drugs.
March 31, 2026
FDA's full approval of Rucaparib for BRCA+ mCRPC, based on TRITON3, positions it as a superior pre-chemotherapy option for this population.
Financial toxicity in gynecologic oncology is pervasive, impacting patient outcomes. Experts discuss its drivers and a navigation program to help.
Experts discuss evolving chronic GVHD care, from PTCI and ORCA-T in prophylaxis to challenges in first-line and options for refractory disease.
SCLC care varies widely. Experts call for broader trial eligibility, biomarker development, and community prep for new therapies like ADCs.
March 30, 2026
FDA approves zongertinib for HER2 TKD-mutated NSCLC, a pivotal shift to upfront, biomarker-driven care with high efficacy and a manageable profile.
Dr. Misty Shields discusses the urgent, multidisciplinary care needed for Small Cell Lung Cancer and the challenges of integrating new therapies.
March 27, 2026
Experts discuss precision oncology in advanced NSCLC, covering targeted therapies for KRAS, NRG1, MET, and ROS1 mutations and testing.
Experts discuss new RAS inhibitors, the critical need for early biomarker testing in GI cancers, and using targeted therapies upfront.
March 26, 2026
Drs. McCann and Nunnery analyze transformative T-DXd trials (DB-11, DB-05) for early HER2+ breast cancer, weighing new efficacy against ILD risks.
March 25, 2026
Dr. Jae Park discusses CAR T-cell therapy for ALL, focusing on Obicell and Brexacel, the critical need for early use, and future directions.
Real-world data validates ctDNA monitoring and confirms pemigatinib's efficacy for FGFR2-altered cholangiocarcinoma.
March 23, 2026
ASCO GU 2026 recap: Practice-changing data in bladder (EV+Pembro), RCC (Belzutifan combos), prostate (PCEC-3), & a non-chemo first for GCTs.
March 20, 2026
In GIST, ctDNA testing at progression is crucial to detect resistance mutations and guide TKI sequencing for improved patient outcomes.
Dr. Wendy Stock discusses new ASH guidelines for AYA-ALL, highlighting the shift to pediatric-inspired therapies to improve survival outcomes.
March 18, 2026
A chemo-free combo of blinatumomab & ponatinib shows 95% remission in Ph+ B-ALL, enabling transplant-free survival with a favorable safety profile.
March 17, 2026
Experts dissect data on menin inhibitors for KMT2A & NPM1 AML, covering efficacy, safety, and their evolving role in patient care.
March 13, 2026
TAMP delivers high-dose chemo directly to pancreatic tumors, bypassing systemic resistance. Early trials show improved survival & lower toxicity.
Experts discuss new trial data for gastric & esophageal cancers, from perioperative DFLOT to targeted therapies and the emerging role of ctDNA.
March 11, 2026
Dr. Sonali Smith discusses CAR T-cell therapy for solid tumors, the critical role of clinical trials, and the rise of cancer in young adults.
March 10, 2026
Experts discuss post-TKI sequencing in EGFR+ NSCLC, emphasizing repeat biopsy for guiding MET targeting and adopting new treatment modalities.
March 8, 2026
Leading oncologists discuss navigating career transitions, work-life harmony, and the critical power of sponsorship for women in medicine.
March 6, 2026
FDA approves Daratumumab+VRd for transplant-ineligible myeloma, boosting response depth and survival based on the Phase III CEPHEUS trial.
Experts discuss breakthroughs in BCG-unresponsive NMIBC, detailing new intravesical and systemic therapies for personalized patient care.
March 5, 2026
TROP2-targeted ADCs like DatoDXD are reshaping lung cancer therapy, offering new options post-chemo but requiring careful toxicity management.
March 3, 2026
Experts review key trial data for immunotherapy and EGFR inhibitors in resectable early-stage NSCLC, optimizing patient treatment pathways.
February 27, 2026
SCLC enters a new era with immunotherapy & targeted therapies like tarlatumab. Dr. Chiang discusses biomarker strategies & holistic patient care.
Experts discuss breast imaging advances, highlighting FES PET-CT's unique role in diagnosing and managing ER+ and lobular breast cancer.
Experts discuss rising anal cancer rates and the PODIUM 303 study, establishing carboplatin/paclitaxel + retafanilumab as the new standard.
February 26, 2026
CheckMate 9LA 6-year data confirm durable survival in metastatic NSCLC with nivo/ipi/chemo, especially in PD-L1 negative & squamous types.
Pumitamig, a PD-L1/VEGF-A bispecific, shows high efficacy in TNBC, offering a new immunotherapy option for PD-L1 negative patients.
Dr. Rashmi Chugh discusses varegacestat, a promising gamma-secretase inhibitor for desmoid tumors, highlighting positive Phase 3 data.
Experts discuss bispecific antibodies in solid tumors, detailing PD-1/CTLA-4, VEGF/PD-1, and DLL-3 agents and their promising clinical data.
February 25, 2026
Evolving standards in cervical cancer care now include immunotherapy and emerging ADCs, redefining treatment for both locally advanced and metastatic disease.
Experts discuss frontline metastatic pancreatic cancer care, balancing NALIRIFOX/FOLFIRINOX, prioritizing quality of life, and championing trials.
Dr. Gesiotto on optimizing ponatinib dosing in CML, the shift to potent frontline TKIs, and the future of personalized, genetically-driven therapy.
Dr. Borghaei shares his journey from Iran to leading thoracic oncology, discussing medical evolution, mentorship, and the human touch in care.
February 24, 2026
ASCO GU 2026 Preview: Experts discuss key trials in prostate, bladder, and RCC, focusing on novel combinations, ctDNA, and radioligands.
February 19, 2026
Experts discuss chondrosarcoma diagnosis, the central role of surgery, and emerging targeted therapies like IDH1 inhibitors and DR5 agonists.
Subcutaneous amivantamab for EGFR+ NSCLC is a win-win, cutting chair time and infusion reactions with potentially better efficacy.
February 18, 2026
Experts discuss epithelioid sarcoma, covering diagnostic delays, multidisciplinary care, and treatment sequencing with chemotherapy vs. tazometastat.
February 13, 2026
In Ph+ ALL, ponatinib is the preferred frontline TKI, often in chemotherapy-free regimens with blinatumomab for deeper, durable responses.
February 11, 2026
Third-line mCRC treatment shifts from aggressive response to stabilization, guided by patient status, prior toxicities & molecular retesting.
Experts decode mesothelioma diagnosis and treatment, comparing nivolumab/ipilimumab vs. chemo-immunotherapy based on histology and patient factors.
February 10, 2026
Targeted therapies like gerodestrin (Ladera study) are showing superiority in ER+ breast cancer, driving a shift toward personalized care.
February 5, 2026
Rethinking dose intensity: Lower upfront Enfortumab Vedotin doses for urothelial cancer may cut toxicity without impacting overall survival.
February 4, 2026
ASCO's 2026 president-elect, Dr. Deb Schrag, outlines priorities for oncology: democratizing research, embracing AI, and ensuring an equitable workforce.
January 31, 2026
Experts discuss the evolving CSCC paradigm, highlighting neoadjuvant immunotherapy, multidisciplinary teamwork, and personalized medicine.
The ASCENT-07 trial for Sacituzumab Govitecan failed to improve first-line outcomes in HR+ breast cancer, maintaining standard chemo's role.
Pirtobrutinib's FDA approval in relapsed/refractory CLL expands second-line treatment options, emphasizing personalized sequencing and safety.
January 30, 2026
Early, reflex biomarker testing is crucial in NSCLC. Pathologist-led, coordinated care is key to reducing delays and optimizing treatment.
Sub-Q Isatuximab via an on-body device is non-inferior to IV for myeloma, proving effective across all body weights and enabling home care.
Experts discuss pivotal trials for metastatic TNBC, detailing the impact of TROP2 ADCs, ICIs, and PARP inhibitors on evolving treatment.
Long-term epcoritamab data show durable responses (>4 years) and confirmed safety in LBCL, supporting its use as a curative third-line option.
Experts outline proactive, multidisciplinary strategies for managing diarrhea, hyperglycemia, and rash from PI3K/AKT inhibitors in breast cancer.
January 29, 2026
Dr. Bardia discusses the Phase III ELEGANT trial, evaluating elacestrant vs. standard endocrine therapy in high-risk, ER+/HER2- early breast cancer.
Beyond JAK inhibitors: Experts discuss novel targeted agents like CALR and JAK2V617F inhibitors poised to reshape MPN treatment paradigms.
Experts discuss managing high-dose methotrexate-induced acute kidney injury, highlighting glucarpidase for rapid clearance and improved recovery.
January 28, 2026
Experts discuss immunotherapy's new role in GYN cancers, from the B96 trial in ovarian cancer to novel cell therapies on the horizon.
January 26, 2026
Experts discuss integrating practice-changing data from DESTINY and PATINA trials, focusing on TDXD's expanding role in breast cancer.
January 22, 2026
Experts discuss ctDNA-guided therapy for HR+/HER2- MBC, focusing on ESR1 mutations and the expanding arsenal of next-gen endocrine agents.
January 21, 2026
Experts discuss transforming SCLC care with immunotherapy (ADRIATIC trial) in limited stage & new agents like tarlatumab for extensive stage.
Experts discuss the rise of RAS inhibitors, detailing pivotal data in lung, pancreatic, and GYN cancers transforming this undruggable target.
January 20, 2026
Dr. Garcia-Manero discusses the GLORIA-IV trial, evaluating lisaftoclax plus azacitidine for higher-risk MDS as a potential new standard of care.
Experts discuss optimizing HR+/HER2- metastatic breast cancer care with CDK4/6i, targeted agents, and novel antibody-drug conjugates.
Experts discuss PSMA-targeted radioligand therapy, from advanced PET imaging diagnostics to pivotal clinical trial data and access barriers.
January 19, 2026
Experts debate adjuvant CDK4/6i, PARPi, & ICIs in early-stage HR+/HER2- breast cancer, focusing on MONARCH-E, NATALY, & OlympiA trial data.
January 16, 2026
Dr. Rahul Banerjee explains how emerging CELMoDs are a new drug class set to replace IMiDs in myeloma, offering superior efficacy and safety.
Experts discuss personalizing HER2+ metastatic breast cancer therapy with data from PATINA, HER2CLIMB-05, and strategies for brain mets.
January 15, 2026
FDA approves Epcoritamab+R² for relapsed follicular lymphoma, establishing a new, highly effective, chemo-free standard based on Epcor FL1 data.
January 9, 2026
FDA approves belantamab mafodotin for myeloma, a new community-based option. Key challenges: ocular toxicity management & sequencing with CAR-T.
January 7, 2026
COMPETE trial: 177Lu-Edotreotide PRRT shows a 10-month progression-free survival benefit over everolimus in metastatic GEP-NETs.
January 5, 2026
Experts discuss de-escalating breast cancer therapy, emphasizing collaboration between surgery and radiation for personalized, less invasive care.
December 31, 2025
Experts discuss the evolving CLL treatment landscape, balancing fixed vs. continuous therapy, patient preference, and sequencing new BTK inhibitors.
FDA-approved Enfortumab Vedotin/Pembrolizumab (EVP) redefines MIBC care, showing huge survival benefits for cisplatin-ineligible patients.
December 29, 2025
ADAURA, LAURA & NeoADURA trials expand osimertinib's role in perioperative EGFR-mutated NSCLC, making early biomarker testing essential.
December 25, 2025
Experts discuss advanced MRI & PET imaging for gliomas, highlighting how FET PET can clarify ambiguous cases of progression vs. pseudoprogression.
December 22, 2025
Dr. Jason Mouabbi discusses ctDNA's transformative role in breast cancer, from screening to predicting recurrence and guiding treatment.
December 18, 2025
Gut microbiome profiling reveals that butyrate loss after stem cell transplant worsens multiple myeloma outcomes, highlighting diet's critical role.
December 17, 2025
Experts discuss Sigvotatug Vedotin, an ADC targeting the highly prevalent IB6 biomarker in NSCLC, as a potential new second-line standard of care.
ASH 2025 update: Pirtobrutinib shows superior PFS vs. chemoimmunotherapy in frontline CLL, but its place among modern therapies is debated.
